Marc Ladanyi, MD
William J. Ruane Chair in Molecular Oncology

The research program in this laboratory focuses on the genomics and molecular pathogenesis of sarcomas and thoracic malignancies, with an emphasis on clinical translation of potential diagnostic markers and therapeutic targets. Dr. Ladanyi also co-directs (with Chris Sander) the Genome Data Analysis Center at Memorial Sloan Kettering, which is part of the TCGA project network.

Examples of recent contributions include the validation of *DUSP4* as a driver gene for 8p losses in *EGFR*-mutant lung adenocarcinomas, the establishment of methods for enhanced detection of the

EGFR T790M secondary mutation in the setting of acquired resistance to EGFR inhibitors, the discovery of *BAP1* mutations in mesotheliomas with 3p losses, the identification of novel, recurrent *HEY1-NCOA2* and *KIF5B-RET* fusions in mesenchymal chondrosarcoma and lung adenocarcinoma, respectively, both based on mining of exon-level expression data, as well as major involvement in the TCGA Network marker papers on the genomics of glioblastoma, ovarian carcinoma, and squamous lung cancer. Ongoing projects are addressing further questions in lung adenocarcinoma, mesothelioma, and several sarcoma types using whole exome and whole transcriptome sequencing, ChIP-seq, Sequenom mass spectrometry genotyping, NanoString expression profiling, RNAi screens, chemical screens, and proteomic approaches.



Ladanyi lab

Featured News

IN THE CLINIC

[A Perfect Match: Molecular Tests Developed at MSK Guide Personalized Treatment for Lung Cancer]

For personalized treatment to work, it's important to analyze each person's tumor for genetic mutations and find the best drugs to target those mutations.

IN THE LAB

[What Was MSK's Role in TCGA, the Groundbreaking Cancer Genomic Study?]

The multicenter project, which yielded dozens of scientific papers on more than 30 different kinds of cancer, has officially drawn to a close.



IN THE LAB

[Scientists Pinpoint a New Cause of Resistance to EGFR-Targeting Drugs]

Multiple copies of a gene called YES1 appear to be responsible for certain precision drugs losing their effectiveness.

View All Featured News

Publications Highlights

Odintsov I, Somwar R, Ladanyi M, Drilon A. (2021). ROS1 at the Crossroads of Clinical

Oncology, Molecular Diagnostics, and Drug Development. JCO oncology practice, 17(1), 15–16.

Hayashi T, Desmeules P, Smith RS, Drilon A, Somwar R, Ladanyi M. (2018). RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 24(6), 1436–1447.

Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, Spraggon L, Qiao H, Lovly CM, Kris MG, Riely GJ, Politi K, Varmus H, Ladanyi M. (2018). YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America, 115(26), E6030–E6038.

Shukla N, Somwar R, Smith RS, Ambati S, Munoz S, Merchant M, D'Arcy P, Wang X, Kobos R, Antczak C, Bhinder B, Shum D, Radu C, Yang G, Taylor BS, Ng CK, Weigelt B, Khodos I, de Stanchina E, Reis-Filho JS, Ouerfelli O, Linder S, Djaballah H, Ladanyi M. (2016). Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors. Cancer research, 76(15), 4525–4534.

Spraggon L, Martelotto LG, Hmeljak J, Hitchman TD, Wang J, Wang L, Slotkin EK, Fan PD, Reis-Filho JS, Ladanyi M. (2017). Generation of conditional oncogenic chromosomal translocations using CRISPR-Cas9 genomic editing and homology-directed repair. The Journal of pathology, 242(1), 102–112.

View All Publications

People

Marc Ladanyi, MD

William J. Ruane Chair in Molecular Oncology

- Molecular pathologist Marc Ladanyi studies the molecular pathogenesis of sarcomas, lung cancer, and mesothelioma.
- MD, McGill University

212-639-6369
Office Phone

View physician profile
Physician profile

Members

Lab
Alumni

Lab Affiliations



Jenna-Marie Dix
Molecular Diagnostics
Research Coordinator

Research Technician
Cheng-Hsiang Daniel Lu
Research Scholar
Marissa Mattar
Research Assistant
Romel Somwar
Assistant Lab Member

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now (https://www.mskcc.org/research-areas/labs/marc-ladanyi/career-opportunities)

Get in Touch

212-639-6369
Office Phone

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Marc Ladanyi discloses the following relationships and financial interests:

- Gilead Sciences, Inc.
  Professional Services and Activities
- Merck & Co Inc.
  Professional Services and Activities
- Paige.AI, Inc.
  Equity; Professional Services and Activities (Uncompensated)
- SOPHiA GENETICS S.A.
  Intellectual Property Rights

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies here . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at ecoi@mskcc.org .

View all disclosures (https://www.mskcc.org/disclosures)